News

This podcast by Dr. Ron Witteles reviews new data on transthyretin amyloid cardiomyopathy (ATTR‑CM), highlighting differences in transthyretin stabilization between…

People carrying the p.V142I mutation in the TTR gene — which is mostly associated with hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) — often have…

Key Points Daratumumab monotherapy in stage IIIB AL amyloidosis showed rapid hematologic responses (75%; median time 1 week) and 65% 6-month survival.Treatment…

ABSTRACTIntroductionLight chain (AL) amyloidosis and transthyretin amyloid cardiomyopathy (ATTR-CM) are the most common types of cardiac amyloidosis. Despite…

ABSTRACTBACKGROUND Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease. Sociodemographic factors may influence time to…

The future of ATTR managementAmyloid cardiomyopathy, particularly transthyretin (ATTR) amyloidosis, has undergone a profound therapeutic transformation over the…

Objective: To evaluate demographics, clinical presentation, diagnostic delay, treatment patterns, genotype-phenotype correlations, and outcomes in patients with…

AbstractBackgroundTransthyretin cardiac amyloidosis (ATTR-CM) is increasingly recognized in elderly patients with conduction disturbances and left ventricular…

Naples, Florida-based Attralus, Inc. announced receipt of US FDA orphan drug designation for zamubafusp alfa (AT-02) for the treatment of immunoglobulin light chain…

AbstractBackground: Volume assessment in cardiac amyloid light chain (AL) amyloidosis is challenging during high-dose chemotherapy and autologous stem cell…